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INTRODUCTION 
 
With 39.5 million people worldwide living with human 
immunodeficiency virus (HIV) infection, acquired immune deficiency 
syndrome(AIDS)  is one of the most destructive pandemics in recorded history. 
AIDS is the late stage of an infection that is generally acknowledged to be 
caused by the HIV. HIV is a retrovirus that attacks and destroys the 
lymphocytes. The targeted destruction weakens the body’s immune system and 
makes the infected person susceptible to infections and diseases that ordinarily 
would not be life threatening. AIDS is considered a blood-borne, sexually 
transmitted disease because HIV spreads through contact with blood, semen, or 
vaginal fluids from an infected person.
1
 
Discovery of HIV
1
 
In September 1983, Luc Montagnier and researchers at the Pasteur 
Institute in Paris, France, isolated and identified a retrovirus and named it as  
Lymphadenopathy associated virus (LAV). Eight months later Gallo’s group  
isolated the same virus in AIDS patients, which they called HTLV-III. LAV and 
HTLV-III were found to be identical and are now referred to as HIV.  
HIV/AIDS IN INDIA 
Prevalence of HIV in India is 0.29% (NACO). 61% are males and 39% 
females. Most common mode of transmission in India is heterosexual which 
comprises 87%. It is increasingly diagnosed in females without apparent risk 
[2] 
 
factors. According to a  study in the British Medical Journal, India has a 
population of approximately 1.4-1.6 million people living with HIV/AIDS
2
. The 
estimated number of HIV infections in India has declined drastically in recent 
years—from 5.5 million in 2005 to below 2.5 million in 2007. These new 
figures are supported by the WHO and UNAIDS
3
. According to the United 
Nations 2011 AIDS report, there has been a 50% decline in the number of new 
HIV infections in the last 10 years in India.
4
 
HISTORY 
The first known case of  HIV was diagnosed by Dr. Suniti Solmon in 
1986 amongst female sex workers in Madras
5
. Later that year, sex workers 
began showing signs of this deadly disease. At that time, foreigners in India 
were travelling in and out of the country. It is thought that these foreigners were 
the ones responsible for the first infections. About 135 more cases came into 
light by 1987. Among these 14 had already progressed to AIDS. Prevalence in 
high risk groups reached above 5% by 1990. 
Setting up HIV screening centres was the first step taken by the 
government to screen its citizens and the blood bank. To control the spread of 
the virus, the Indian government set up the National AIDS Control Programme 
(NACP) in 1987 to co-ordinate national responses such as blood screening and 
health education. In 1992, the government set up the National AIDS Control 
[3] 
 
Organisation (NACO) to oversee policies and prevention and control 
programmes relating to HIV and AIDS. The State AIDS Control Societies 
(SACS) was set up in 25 societies and 7 union territories to improve blood 
safety. In 1999, the second phase of the National AIDS Control Programme 
(NACP II) was introduced to decrease the reach of HIV by promoting behaviour 
change. The prevention of mother-to-child transmission programme (PMTCT) 
and the provision of antiretroviral treatment were materialized. In 2007, the 
third phase of the National AIDS Control Programme (NACP III) targeted the 
high-risk groups, conducted outreach programmes, amongst others.  
EPIDEMIOLOGY 
Despite being home to the world's second-largest population suffering 
from HIV, the AIDS prevalence rate in India is lower than in many other 
countries. In 2007, India's AIDS prevalence rate stood at approximately 
0.30%—the 89th highest in the world.7 As per UNDP’s report in 2010, India 
had 2.39 million HIV population at the end of 2009, up from 2.27 million  in 
2008. Adult prevalence also rose from 0.29% in 2008 to 0.31% in 2009
6
.The 
states with high HIV prevalence rates include Manipur (1.40%), Andhra 
Pradesh (0.90%), Mizoram (0.81%), Nagaland (0.78%), Karnataka (0.63%) and 
Maharashtra (0.55%).In the most severely affected state, Maharashtra, 
seropositivity was 60% among sex workers, 14–60% in sentinel STD clinics, 
and over 2% among women attending antenatal clinics (NACO, 1999, p. 4).
8
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HEMOSTATIC ABNORMALITIES
9
 
  HIV infection is becoming more complex. With the introduction of 
cART, HIV infection is slowly evolving into a chronic disease. Highly active 
antiretroviral therapy (HAART) has greatly reduced the risk of early death from 
opportunistic infections and extended the lifespan of people infected with the 
HIV. Thus, many complications and organic damage in the HIV-infected 
population emerge. In the recent years, hemostatic abnormalities have gained 
their significance in HIV infection. HIV-related thrombocytopenia is the most 
common hemostatic disorder with a high morbidity and affects patients from 
every risk group independently of age, sex, or stage of infection. Two 
mechanisms are responsible for this are bone marrow failure and immunological 
disorders, namely, circulating immune complex deposited on the platelet 
membrane and the production of auto-antibodies directed against platelets. The 
treatment of choice is cART. In addition, there are some abnormalities in the 
fluid phase of the coagulation cascade which can produce bleeding or 
thrombosis in the HIV patient. The most common are a prolonged partially 
activated thromboplastin time test, the production of a lupus anticoagulant and 
anticardiolipin antibodies, and several abnormalities in the natural-occurring 
anticoagulants. The knowledge of these hemostatic abnormalities and its early 
identification in the HIV seropositive patient allows a more rational care of 
these patients.
9
 
 [5] 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
          
         
1. To analyse the hemostatic status of HIV infected individuals 
irrespective of their ART status. 
  
2. To analyse the association of CD4 count, WHO staging,                                                           
cART intake, and comorbidities independently with the hemostatic 
parameters. 
 
[6] 
 
REVIEW OF LITERATURE 
 
Disorders of the hematopoietic system including lymphadenopathy, 
anemia, leukopenia, and/or thrombocytopenia are common throughout the 
course of HIV infection and may be the direct result of HIV, manifestations of 
secondary infections and neoplasms, or side effects of therapy. Initiation of 
cART will lead to reversal of most hematologic complications that are the direct 
result of HIV infection.
10
 
Causes of  bone marrow suppression in patients with HIV infection
10
 
 
 
 HIV infection 
 Mycobacterial 
infections 
 Fungal infections 
 B19 parvovirus 
infection 
 Lymphoma 
 Medications 
Zidovudine  
Dapsone  
Trimethoprim/sulfamethoxazole 
Pyrimethamine  
5-Flucytosine  
Ganciclovir  
Interferon   
Trimetrexate  
Foscarnet 
 
[7] 
 
HEMOSTATIC ABNORMALITIES IN HIV 
THROMBOCYTOPENIA 
Thrombocytopenia is relatively common during the course of HIV 
infection, occuring in approximately 40% of patients and serving as the first 
symptom or sign of infection in approximately 10%
11,12
. Severe 
thrombocytopenia was first observed in contaminated homosexual males. 
Thrombocytopenia may be an early consequence of HIV infection. 
Approximately 3% of patients with untreated HIV infection and CD4+ T cell 
counts >400 cells/microlitre have platelet counts <1,50,000/mm
3
. For untreated 
patients with CD4+ T cell counts <400 cells/microlitre, this incidence increases 
to 10%. In patients receiving ART, thrombocytopenia is associated with 
hepatitis C, cirrhosis, and ongoing high-level HIV replication. After controlling 
for multiple factors, thrombocytopenia was significantly associated with shorter 
survival (risk ratio 1.7)
12
. 
HIV RELATED IMMUNE THROMBOCYTOPENIC PURPURA 
Clinically, thrombocytopenia in patients with HIV  resembles the 
thrombocytopenia seen in patients with idiopathic thrombocytopenic purpura. In 
patients with early stage HIV infection with intact CD4 counts, low viral load, 
no hepatosplenomegaly or adenopathy, and an otherwise normal complete blood 
count, HIV-associated immune thrombocytopenic purpura is the most likely 
[8] 
 
diagnosis. With progression of the underlying HIV disease, secondary causes of 
thrombocytopenia should receive greater consideration
12
. 
The two major components of the pathophysiology of HIV-associated 
thrombocytopenia are immune-mediated destruction of platelets, and  a defect in 
bone marrow production as a result of the interaction between HIV and 
megakaryocytes through several pathways, which causes suppression of platelet 
production. Often both components can be present simultaneously. Elevated 
levels of platelet-associated Ig G and/or circulating immune complexes often 
indicate that immune-mediated destruction of platelets in HIV-infected 
individuals with thrombocytopenia is occurring. These patients may have a 
marked increase of platelet-associated Ig G, Ig M, C3, and C4 levels. The 
immune complexes are thought to contain anti-HIV gp120 and anti-antibodies 
(anti-idiotypes) directed against the anti-HIV antibodies. In a few patients, 
cross-reactivity of antibodies against HIV gp120/gp160 with platelet 
glycoprotein GPIIb/IIIa has been shown.
11
 Because megakaryocytes are infected 
by HIV, the “anti-platelet” antibodies could also be directed against HIV 
proteins expressed on megakaryocytes or platelets. Although many patients 
have immune-mediated platelet destruction as an important or predominant 
cause of their thrombocytopenia, it is not thought to be helpful diagnostically to 
obtain “platelet antibodies” in the evaluation of a thrombocytopenic HIV-
infected patient because the antibody tests have both high false-positive and 
false-negative rates.
12
                                                                                                                                                                                                         
[9] 
 
Human megakaryocytes bear a CD4+ receptor capable of binding HIV
13
 
and HIV-1 can be internalized by human megakacyocytes
14
.The HIV-1 
coreceptor  CXCR4  is present on megakayocytic progenitors, megakaryocytes 
and platelets. Specific ultra structural damage in HIV infected megakaryocytes 
consisting of blebbing and vacuolization of surface membrane
15
. A casual 
observation that bone marrow biopsies of HIV-infected individuals seem to 
exhibit an unusually large number of denuded megakaryocyte nuclei (DN-MK) 
prompted a study comparing megakaryocyte nuclei of 20 HIV-seropositive 
individuals with those of 10 patients with HIV-negative idiopathic 
thrombocytopenic purpura and 10 hematologically normal subjects. In normal 
marrows the number of  DN-MK average 2.1 + 0.5 SE per 10 low power field. 
In patients with ITP the average number was 6.5 + 1.4 SEM, whereas HIV-ITP 
marrows had an average of 42.5 + 3.7 SEM. Electron microscopy of AIDS 
megakaryocytes exhibited ballooning of the peripheral zone to an extent not 
seen by us in any other myelodysplastic syndromes. These observations support 
the concept that the pathophysiology affecting platelets/megakaryocytes in 
HIV-infection should not be equated with the destructive process underlying 
other immune thrombocytopenias.
15 
In individuals with advanced HIV disease, other causes of 
thrombocytopenia, such as opportunistic infections, medication side effects, and 
infiltrative malignancies, are more likely. This is particularly true when there 
are associated physical examination findings or other cell line deficits. 
[10] 
 
Opportunistic infections can cause thrombocytopenia, especially histoplasmosis 
and cryptococcosis. Medications used in the management of HIV that are most 
commonly associated with thrombocytopenia include ganciclovir (48%), 
pentamidine (18%), and trimethoprim-sulfamethoxazole (3%). Rifabutin, 
clarithromycin, zidovudine, and didanosine are less commonly associated with 
thrombocytopenia.
12  
Experimental tests with potential future use in the diagnosis of HIV-
associated thrombocytopenia include the following: 
 Measurement of thrombopoietin levels: Thrombopoietin levels are almost 
always normal in HIV-associated thrombocytopenic purpura unless the 
disease has progressed to a very late stage and the number of marrow 
megakaryocytes is decreased. 
 Measurement of glycocalicin: Glycocalicin is the carbohydrate-rich 
portion of platelet membrane glycoprotein Ib-a Symbol, which has been 
reported to be increased when there is increased platelet turnover. 
 Platelet reticulocyte counts: Platelet reticulocyte counts are thought to 
reflect the percentage of young platelets.
12
 
When these tests are available to the general practitioner, they may allow better 
estimation of the rate of platelet production. 
 
[11] 
 
TREATMENT FOR HIV RELATED THROMBOCYTOPENIA 
Whatever the cause, it is very clear that the most effective medical 
approach to this problem has been the use of cART
10
. In a retrospective study, 
15 patients with HIV-associated severe thrombocytopenia (platelet count < 
50×10
9
/l), mostly antiretroviral experienced (13/15), underwent HAART for at 
least 6 months (median 21; range 6–41 months) during which the platelet (PLT) 
count and plasmatic HIV-RNA were monitored. The PLT response was 
compared to that observed in previously treated patients with  zidovudine 
(AZT) monotherapy. HAART induced a significant increase in the PLT count 
(P =0.01) within the third month which was sustained up to the sixth month of 
therapy. No severe thrombocytopenia relapse was observed among eight PLT 
responders followed for longer than 6 months (median 27; range 7–41 months). 
The PLT increase after HAART was similar to that observed with AZT 
monotherapy, but a greater number of HAART patients were antiretroviral-
experienced. HAART determined a PLT response in 10/13 subjects whose 
thrombocytopenia had not improved after previous AZT monotherapy. After 6 
months of HAART, a complete platelet response occurred more frequently in 
patients with undetectable plasma HIV-RNA levels (P=0.01).
19 
For patients with platelet counts <20,000/mm
3
 ,a more aggressive 
approach combining IV Ig or anti-Rh Ig for an immediate response with cART 
for a more lasting response is appropriate. Rituximab has been used with some 
[12] 
 
success in otherwise refractory cases. Splenectomy is a rarely needed option and 
is reserved for patients refractory to medical management. 
HIV RELATED THROMBOTIC THROMBOCYTOPENIC PURPURA 
In patients with early HIV infection, thrombocytopenia has also been 
reported as a consequence of  classic thrombotic thrombocytopenic purpura. 
This clinical syndrome, consisting of fever, thrombocytopenia, hemolytic 
anemia, and neurologic and renal dysfunction, is a rare complication of early 
HIV infection. HIV related TTP generally has milder cause and better response 
to therapy than classical TTP
16
. HIV can infect endothelial cells, and viral P24 
antigen has been detected in splenic endothelial cells, spinal cord specimens and 
in bone marrow microvascular endothelial cells
17
. TNF-α and IL-1β are 
increased in HIV infection could potentially lead to increases in endothelial 
expression of adhesion molecules such as vascular cell adhesion molecule-1, 
intercellular adhesion molecule and E-selectin promoting localization of 
inflammatory cells to endothelium. Endothelial cells from small blood vessels 
undergo apoptosis when exposed to plasma from patients with TTP
18
.As in 
other settings, the appropriate management is the use of salicylates and plasma 
exchange.
10
 
THROMBOEMBOLISM 
The incidence of venous thromboembolic disease such as deep-vein 
thrombosis or pulmonary embolus is approximately 1% per year in patients with 
[13] 
 
HIV infection. This is approximately 10 times higher than that seen in an age-
matched population. Among the factors associated with clinical thrombosis are 
age over 45, history of an opportunistic infection, lower CD4 count and 
estrogen use. Abnormalities of the coagulation cascade including decreased 
protein S activity, increase in factor VIII, anticardiolipin antibodies, or lupus-
like anticoagulant have been reported in more than 50% of patients with HIV 
infection.
10 
Even if lupus anticoagulant could be evidenced in asymptomatic 
PLHAs, it frequently occurred during acute opportunistic infections such as 
Pneumocystis carinii. 
In one study in which the protein S level was measured in 34 HIV-
infected children with no previous history of thrombosis, decreased levels of 
protein S (total and functional) were found in 76.5% of the patients.
21
These 
decreased levels of protein S were more prevalent in subjects with CD4 counts 
<200 cells/mm
3
. Long-term studies are needed to determine the cumulative risk 
of thrombotic complications caused by these abnormalities and to better 
describe the complete coagulation profile in these patients.
12 
Abnormalities of the fibrinolytic system were also reported, such as 
increased levels of both tissue-type plasminogen activator and type 1 
plasminogen activator inhibitor or decreased levels of histidine-rich 
glycoprotein. Even if the acute phase response could play a key-role, the 
pathogenesis of these abnormalities is not fully understood, so far. In addition, 
their clinical consequences have not been extensively investigated, but 
[14] 
 
hemorrhage appeared to be uncommon. Moreover, D-Dimer levels were found 
increased in HIV-infected patients, suggesting that HIV-infection might be 
associated with a prothrombotic state, which could lead to clinical thrombosis in 
some HIV-infected patients (2%).
20
 Recent epidemiological studies emphasize 
the increased incidence of thromboembolic events including myocardial 
infarction in the HIV-infected population after the introduction of highly active 
antiretroviral therapy. The use of protease inhibitors in particular is 
implicated.
23
 
CHRONICITY ASSOCIATED WITH VENOUS THROMBOTIC DISEASE: 
HIV infection has changed into a chronic infection with the chance of 
developing long-term complications. Vascular complications are frequently 
reported in the current literature. HIV and treatment by highly active 
antiretroviral therapy (HAART) are associated with many cardiovascular risk 
factors. An increased risk of arterial cardiovascular complications was found in 
a number of studies. However, data about the risk of venous thrombotic disease 
(VTE), including potentially fatal conditions like pulmonary embolism, were 
limited. In a systematic review of the literature, ten relevant epidemiological 
studies were identified that investigated the risk of venous thrombotic disease in 
HIV-infected patients. The incidence was increased two- to tenfold in 
comparison with a healthy population of the same age. However, these studies 
were mainly retrospective cohort studies that were prone to selection bias, 
[15] 
 
confounding factors were not always mentioned and in all but three control 
populations were missing. An increased risk of venous thrombotic disease in 
HIV-infected patients could be explained by the presence of a hypercoagulable 
state, characterised by an increase in procoagulant factors, such as endothelial 
tissue factor expression and thrombogenic properties of microparticles, and a 
decrease in anticoagulant factors, including anti-thrombin III, Heparin cofactor 
II and the protein C pathway. Furthermore, the risk of VTE was associated with 
an increased risk of infections and autoimmune haemolytic anaemia, and was 
weakly associated with HAART.
22
 
The coagulation abnormalities seem to correlate with the degree of 
immunosuppression, as indicated by a change in the CD4+ cell count. 
Abnormalities of protein C, including decreased levels of functional protein C 
or antigenic protein C, have been identified in patients infected with HIV.
24
 
Cases of antithrombin III deficiency in patients with HIV who experienced 
thrombotic events have been reported,
[25]
 and most cases of antithrombin III 
deficiency are attributed to urinary loss (HIV-related nephropathy).
[26]
 The 
prevalence of lupus anticoagulants and anticardiolipin antibodies in patients 
infected with HIV has been reported to be as high as 53% to 70% and 46% to 
90%, respectively.
27
 Although the association of lupus anticoagulants with 
thrombosis in HIV infection is rare, thrombotic complications, such as transient 
ischemic attack, mild thrombotic stroke, avascular necrosis, edema of skin, and 
[16] 
 
skin necrosis, have been documented in patients with HIV infection who have 
positive antiphospholipid antibodies.
28
 
ANTI PHOSPHOLIPID ANTIBODIES: 
In  HIV infected persons, the presence of APL is associated neither with 
the stage of the disease, the CD4 cell count, the viral load nor with a 
prothrombotic state in vivo. Abuaf and colleagues 
[29]
 found that the presence of 
APL in HIV-infected patients was not associated with lupus anticoagulant, a 
biological false positive test for syphilis, thrombocytopenia or thrombosis. 
Moreover, APL found in HIV infection are not anti-β2-glycoprotein I 
antibodies
29-31. 
On the contrary, APL encountered in systemic lupus 
erythematosus are associated with an increased thrombin generation
32
 and with 
anti-β2-glycoprotein I antibodies 33. Taken together, these  demonstrate that 
APL encountered in HIV infection do not share the features of immune APL, 
and that the presence of APL does not warrant anticoagulant treatment in HIV-
positive patients. 
PROTEASE INHIBITORS AND VENOUS THROMBOSIS: 
In a study for 42-month period, 28 adult male homosexuals with AIDS 
experienced 34 thrombotic events. All but three received HAART regimen, two 
a successful round of double nucleoside analogue therapy, and one patient 
received no treatment. Median age of group was 38.5 years (range, 24 to 56 
[17] 
 
years). Median time from HIV infection to thrombosis was 40.5 months (range, 
3 to 108 months). No patient had previous thrombosis, family history of 
thrombosis, or prothrombotic conditions. There were 31 deep vein thromboses, 
two pulmonary thromboembolisms, and one renal vein thrombosis. Six patients 
had two thrombotic events. The rate of thrombosis during the 42-month study 
period was 1.52% (cumulative incidence = 0.30%/year), while the rate of 
thrombosis in 600 patients before the era of protease inhibitor therapy was 
0.33% (cumulative incidence approximately 0.055%/year) (p < 0.001). Due to 
high incidence of thrombotic recurrences and hemorrhagic complications while 
using oral anticoagulants, acetylsalicylic acid was initiated; no thrombotic 
episodes were recorded while using this drug. Protein C and protein S 
deficiency were found in nine and two patients, respectively. Two patients had 
lupus anticoagulant and two activated protein C resistance (APCR) without 
Factor V Leiden mutation (APCR test was negative after initial screening). 
Fifteen patients had no thrombophilic abnormalities. These data suggest that 
protease inhibitors could be a risk factor for venous thrombosis not due to 
thrombophilic abnormalities but likely related to abnormalities in platelets or 
endothelium
23
. 
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MATERIALS & METHODS 
 
 
 
SUBJECTS 
 
Patients with HIV infection attending ART clinic and those who are inpatients 
in Rajiv Gandhi Government General Hospital, Chennai.  
 
 
PERIOD OF STUDY 
 
6 months 
 
 
 
DESIGN OF STUDY 
 
Cross-sectional study 
 
 
 
CONSENT                      
 
Informed  consent from all the patients         
 
 
 
 
ELIGIBILITY CRITERIA 
                       
                
1. All patients with HIV infection 
2. HIV infection proven by ELISA & western blot assay. 
[19] 
 
EXCLUSION CRITERIA 
 
  Patients with inherited bleeding disorders or on anticoagulants. 
  Patients who had previous thrombosis, family history of thrombosis                              
and   prothrombotic conditions. 
  Patients were excluded if they refused to become part of study 
  Patients less than 14 years of age and pregnant women  
 
 
METHODOLOGY 
 
All patients with HIV infection attending Govt. General Hospital during 
the study period were evaluated for the hemostatic parameters in the study. The 
parameters were platelet count, prothrombin time, activated partial 
thromboplastin time, plasma fibrinogen and serum lactate dehydrogenase. 
Special investigations like D-Dimer and LAC were done when required. 
Absolute CD4 count done by flow cytometric analysis was obtained. They were 
staged as per the WHO clinical staging given by the National AIDS control 
organisation (NACO). 
 
 
 
[20] 
 
Investigation details   
Complete history and thorough physical examination of  HIV infected 
individuals and  routine  blood investigations and coagulation profile .                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   
Data collection and methods 
 
Collection of data as per proforma with consent from HIV infected patients in 
Medicine wards and OP department.                                                                                                                                                                                             
   
Analysis                          
Data analysed using statistical package-SPSS software 
 
Conflict  of  interest      : Nil.  
   
Financial  data            : Nil 
 
 
 
 
 
 
[21] 
 
Normal Values of parameters Assessed 
10
 
                                                      Adult Male                 Adult Female 
 
Haemoglobin                                     13.3 to 16.2 g/dl                 12.0 to 15.8 g/dl 
 
CD4 count                                                         600-1500 cells/mm
3 [34]
 
 
Platelet count                                                     1.65 to 4.15 lakh / mm3 
 
Prothrombin time                                              12.7 to 15.4 seconds 
 
Activated partial thromboplastin time              26.3 to 39.4 seconds 
 
Serum lactate dehydrogenase                           115 to 221 units/litre 
 
Plasma fibrinogen                                             233 to 496 mg/dl 
 
D-Dimer                                                            0.22 to 0.74 microgram/ml 
 
 
 
 
[22] 
 
LABORATORY EVALUATION OF HEMOSTASIS 
[40]
 
 
PLATELET COUNT 
Modern hematology analyzers perform a platelet count by electrical 
impedance or light scattering techniques that are accurate to ±5% in the range of 
1000 - 3,000,000 platelets/μl. A measurement of platelet volume  is provided at 
the same time, as well as a platelet size distribution curve. Automated platelet 
counts can be affected by platelet aggregates due to spontaneous aggregation, 
cold agglutinins, EDTA anticoagulants ("spurious thrombocytopenia, 
pseudothrombocytopenia") or particulate debris, such as red or white cell 
fragments("spurious thrombocytosis").
35-37
In addition, hematology analyzers 
may overestimate the platelet count in severe thrombocytopenia.
(38)
 Therefore, 
confirmation of atypical platelet counts by manual inspection of a peripheral 
smear is essential. If necessary, platelet counts can be performed in a 
hemocytometer by phase contrast microscopy to an accuracy of ±10-20%. 
 
BLEEDING TIME 
The Ivy skin bleeding time is an imprecise manual screening assay of 
primary hemostasis that was widely utilized in the past as a diagnostic assay for 
patients with suspected bruising and bleeding disorders, as a therapeutic guide 
in actively bleeding patients, and as a predictor of hemorrhage in the general 
population of patients undergoing surgery or invasive procedures
39
.A blood 
[23] 
 
pressure cuff is placed on the upper arm and inflated to 40 mm Hg to provide 
uniform capillary pressure, and a standardized incision is made on the volar 
surface of the forearm with a standard cutting device, such as the Surgicut and 
the Triplett and Tip Tripper Bleeding Time Devices. Blood is wicked from the 
incision with filter paper at 30-second intervals until bleeding ceases. The result 
is reported in seconds as the bleeding time.
41,42
 
The bleeding time is determined by many physiologic factors, including 
skin resistance, vascular tone and integrity, and platelet adhesion and 
aggregation. Thus, a prolonged bleeding time may reflect an intrinsic platelet 
function defect, Von Willebrand disease, vascular anomaly, or medications that 
affects platelet function, such as aspirin. If the actual bleeding time exceeds the 
expected bleeding time by five minutes, a platelet function defect may be 
suspected. Unfortunately, the precision, accuracy, and reproducibility of the 
bleeding time are severely impaired by factors such as the thickness and 
vascularity of the skin, the location of the incision, skin temperature, wound 
depth, and patient anxiety. Because of its imprecision, the bleeding time must 
be used with extreme caution in a patient care setting. The US Food & Drug 
Administration no longer accepts bleeding time data in patients as a surrogate 
marker for the evaluation of new hemostatic drugs, and it is no longer indicated 
for the preoperative screening for hemostatic defects
43-46
.The routine utilization 
of the bleeding time for the diagnostic evaluation of patients with von 
[24] 
 
Willebrand disease, storage pool disorder, and other hereditary mucocutaneous 
hemorrhagic diseases has been questioned.
47
  
 
PROTHROMBIN TIME 
The PT provides a functional determination of the integrity of the 
extrinsic (tissue factor) pathway of coagulation and is sensitive to the vitamin-K 
dependent clotting factors (factors II, VII, IX, and X) as well as to factors of the 
common pathway (fibrinogen,prothrombin, factor V, factor X). The PT is a 
widely used laboratory assay for the detection of inherited or acquired 
coagulation defects related to the extrinsic pathway of coagulation, and is the 
standard test for monitoring oral anticoagulation therapy(coumadin).
48,49
In the 
PT an aliquot of test platelet-poor plasma is incubated at 37
o
C with a reagent 
containing a tissue factor, phospholipid (thromboplastin), and CaCl2. The time 
required for clot formation is then measured by one of a variety of techniques 
(photo-optical, electromechanical,etc.). The result is reported in seconds 
(prothrombin time), or as a ratio compared to the laboratory mean normal 
control (prothrombin ratio, PTR). The PT is critically dependent on the 
characteristics of the thromboplastin used in the assay, as well as manner of 
blood coagulation, the type of container, the type of anticoagulant, specimen 
transport and storage conditions, incubation time and temperature, assay 
reagents, and the method of end point detection. This means that patients on 
[25] 
 
coumadin will have different clotting times when tested in different 
laboratories, so a means of standardization of results must be employed. 
The International Normalized Ratio (INR) was introduced by the World 
Health Organization (WHO) in the early 1980’s as a means of standardizing PT 
results.
50
 For this purpose, a very responsive batch of human brain extract was 
designated as the first International Reference Preparation (IRP), and a 
correction factor (International Sensitivity Index, ISI) was developed to 
correlate the sensitivity of commercial thromboplastin preparations to the IRP. 
By definition, the ISI of the first IRP was 1.0. An additional term, the INR, was 
introduced to compare a given prothrombin ratio measurement to the IRP. 
Commercial vendors of thromboplastin preparations supply the ISI with each 
reagent lot. If the ISI is known, the INR for each clotting time is easily 
calculated. However, the ISI can be affected by instrumentation and other 
laboratory factors and thus must be verified by each testing site according to 
standards of the College of American Pathologists. Unfortunately, even with the 
INR, current prothrombin reagent/instrument calibration techniques are 
insufficient to provide good intralaboratory agreement.
51,52
 
ACTIVATED PARTIAL THROMBOPLASTIN TIME 
The partial thromboplastin time (PTT) is the clotting time obtained when 
“partial thromboplastin” is added to plasma. Partial thromboplastin is the 
phospholipid fraction of a tissue extract, and differs from a complete tissue 
extract (i.e., “thromboplastin”) by the lack of tissue factor. The PTT is sensitive 
[26] 
 
to the intrinsic pathway of coagulation, but is most sensitive to the contact 
factors (i.e., factor XII, prekallikrein, high molecular weight kininogen) when a 
particulate “activating agent” (i.e., silica, celite, kaolin, micronized silica, 
ellagic acid) is added to the reaction (activated PTT, aPTT). Many different 
phosophlipid reagents animal and plant origin, such as cephalin, have been used 
as partial thromboplastins, and a variety of activating substances are in use
53
.In 
the aPTT an aliquot of undiluted, platelet-poor plasma is incubated at 37
o
C with 
an activator and phospholipid (partial thromboplastin). CaCl2 is then added, and 
the time required for clot formation is measured by one of a variety of 
techniques (photo optical, electromechanical, etc.). The aPTT result is reported 
as the time required for clot formation after the addition of CaCl2. The aPTT is 
functional determination of the intrinsic (factors XII, XI, IX, VIII, V, II,I,) and 
common pathways of coagulation.
54,55
.The aPTT is utilized to detect congenital 
and acquired abnormalities of the intrinsic coagulation pathway, monitor 
patients receiving heparin or coagulation factor replacement therapy, and to 
detect inhibitors of the intrinsic and common pathways.
56
.The aPTT clotting 
time may be influenced by many pre-analytical and analytical variables and 
caution must be used in the interpretation of the result. Preanalytical variables 
include slow or difficult specimen collection, an improper blood:anticoagulant 
ratio, failure to promptly mix the blood with the citrate anticoagulant, improper 
transport or storage, or a prolonged interval between specimen collection and 
analysis. The sensitivity of the assay to factor deficiencies, inhibitors, and 
[27] 
 
heparin also varies with the reagents used in the assay. Because of these 
variables, a normal aPTT result does not exclude a mild coagulation factor 
deficiency or the presence of a low titre or slow-reacting inhibitor. However, a 
significant prolongation of the aPTT indicates the presence of a factor 
deficiency (VIII, IX, XI, XII, prekallikrein, HMWK), while prolongation of 
both the PT and aPTT suggests a deficiency of factor I, II, V, or X. The aPTT is 
not affected by deficiencies of factor VII or XIII. Numerous modifications of 
the aPTT have been described for the functional analysis of specific 
coagulation-related substances which include the reptilase time, the Bethesda 
assay, protein C and protein S activity, and several assays for lupus 
anticoagulants (dilute Russell viper venom time[dRVVT], platelet neutralization 
test, and hexagonal phospholipid assay. 
Specific anti-factor VIII antibodies (inhibitors) are a serious medical 
problem for patients with hemophilia. Mixing studies can detect the presence of 
inhibitors, but other assays are required for the precise measurement of antibody 
activity necessary for patient care.
57
 The Bethesda assay is a modified aPTT 
based on the ability of factor VIII inhibitors to neutralize factor VIII activity in 
normal plasma. A series of dilutions of patient plasma are added to a standard 
amount of normal plasma and assayed for factor VIII levels after two hours 
incubation at 37
0
C: the titre at which half of the FVIII activity remains is used 
to calculate the “Betheda units” of inhibition. Several modifications of the 
Bethesda assay have been developed to improve its sensitivity.
58-60
The new 
[28] 
 
Oxford assay is similar, but uses factor VIII concentrate as the source of  factor 
VIII. Enzyme immunoassay, gel techniques, and other methods have been also 
used to detect inhibitors. 
PLASMA MIXING STUDIES (Clotting Factor Inhibitor Screen, 
Circulating Anticoagulant Screen) 
A prolonged clotting test (i.e., PT, aPTT, and/or thrombin time) indicates 
the presence of a factor deficiency or inhibitor of coagulation. The plasma 
mixing study is the initial step in the evaluation of a prolonged clotting time. 
The goal of a mixing study is to determine if the prolonged clotting time is 
shortened or “corrected” by mixing the test plasma with equal volume of normal 
pooled plasma (NPP; also called citrated normal plasma, CNP). Even a 
profound deficiency of a clotting factor, such as the 1% factor VIII level 
encountered in severe hemophilia, will be corrected to the normal range by 
mixing with NPP, since a 50% level of any factor will still yield a normal 
clotting time. “Factor assays” are then performed to identify the deficient 
clotting factor. The failure of a prolonged clotting test to correct in the mixing 
study indicates the presence of a “inhibitory” substance that is preventing 
clotting from occurring. Unfortunately, this is somewhat difficult to accomplish 
since there are several different types of inhibitors (also called “circulating 
anticoagulants”). “Specific inhibitors” are immunoglobulins with specificity for 
phospholipid ("lupus anticoagulants") or a specific clotting factor ("factor 
inhibitors"). “Global” or “non-specific” inhibitors affect more than part of the 
[29] 
 
clotting process and include fibrin(ogen) degradation products, some pathologic 
antibodies such as monoclonal paraproteins, and drugs such as heparin. Clinical 
and other laboratory clues are necessary to identify the inhibitor. For example, 
lupus anticoagulants are usually not associated with clinical bleeding, while 
specific factor inhibitors frequently cause bleeding. Generally, factor 
deficiencies produce a complete correction of the prolonged clotting time (i.e., 
corrected to within the normal range), specific antibodies show very little, if any 
correction, and non-specific may show a “partial correction,” (i.e.,shortened 
clotting time but not to within the normal range). The presence of heparin and 
other nonspecific inhibitors can be confirmed by other coagulation tests such as 
the thrombin clotting time and reptilase time, while lupus anticoagulants are 
identified by a phospholipid-sensitive test such  as the dilute Russell viper 
Venom time (dRVVT). The last clue is provided by the effect of incubation on 
the activity of the inhibitor. An “immediate” mixing study is performed by 
mixing equal amounts of the "test" plasma with NPP (1:1 mix) and immediately 
performing a clotting time(i.e., PT, aPTT, or TT) on the mixed plasma 
specimen.
61-63
 Most factor inhibitors (except factor VIII) and a most lupus 
anticoagulants (“fast reacting inhibitors”) produce an immediate clotting time 
inhibition and do not require incubation. In contrast, most factor VIII inhibitors 
and some lupus anticoagulants (15%) are weak and/or time dependent(“slow 
reacting inhibitors”), and require incubation of the 1:1 plasma mixture at room 
temperature or 37
oC for one or two hours (“incubated mix”) to cause 
[30] 
 
prolongation of the clotting time.
64 
A false diagnosis of a factor deficiency can 
result without incubation, since slow-reacting inhibitors may correct the 
immediate mix. The markedly prolonged aPTT of coagulation factors, V and 
VIII, during incubated studies. Common criteria for correction of the patient 
sample include to within 5 seconds, or to within 10% or 15% of the NPP value. 
PLASMA FIBRINOGEN 
              Fibrinogen is the most abundant clotting protein in the plasma, with a 
normal plasma level ranging from 200-400 mg/dl. The quantitative 
determination of plasma fibrinogen is essential in the diagnosis and 
management of many coagulopathies. In addition, since plasma fibrinogen 
levels are increased in some patients who develop myocardial infarction and 
stroke, there is interest in the measurement of fibrinogen for thrombotic risk 
assessment.
65 
The washed clot method (total clottable fibrinogen assay,World 
Health Organization method) is the reference technique for fibrinogen 
determination. In this technique, citrated plasma is incubated for an extended 
period of time with thrombin in the presence of epsilon aminocaproic acid 
(EACA) to prevent digestion of the fibrin clot by plasmin. Other serum proteins 
are removed by washing, the clot is dissolved in concentrated urea, and the 
fibrinogen concentration is measured colorimetrically.
66
 This technique is 
unsuitable for the determination of the large number of specimens encountered 
in the clinical laboratory, but, unfortunately, the accurate and precise 
measurement of fibrinogen with the automated coagulometer has proven 
[31] 
 
difficult. Immunoassays are rarely used. In spite of their flaws, the Von Clauss 
technique and the Clotting Rate Assay (Kinetic Fibrinogen Assay) are most 
widely used in the clinical laboratories. The Von Clauss technique is based 
upon the principle that when a high concentration of thrombin is added to 
plasma diluted in buffer (1:5 or 1:10), the effects of clotting inhibitors are 
diminished and the clotting time is directly proportional to the level of clottable 
fibrinogen.
67 
Clotting times of patient plasma are read on a standard curve made 
with purified fibrinogen of known concentration to interpolate a fibrinogen level 
in the patient. The assay is accurate in the range of approximately 50 – 800 
mg/dL. Since the von Clauss technique requires a high level of technical skill, a 
more recent prothrombin time-based kinetic assay is preferred by many 
laboratories. In this assay, the rate of increase in plasma turbidity is measured at 
450 nm during the thrombin-catalyzed conversion of fibrinogen to fibrin.
68
 This 
kinetic assay is rapid, economical, and can be fully automated.
69 
Many studies 
have shown that fibrin degradation products cause an overestimation of the 
fibrinogen level by the washed clot and immunologic assays, and an 
underestimation by the clot-based techniques.
65
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WHO clinical staging of HIV disease in adults and 
adolescents 
 
Clinical stage I 
 
Asymptomatic 
 
Persistent generalized lymphadenopathy  
 
Performance scale 1:asymptomatic,normal activity 
 
Clinical stage II 
 
Moderate unexplained weight loss (under 10% of presumed or measured body 
weight) 
 
Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, 
pharyngitis) 
 
Herpes zoster 
 
Angular cheilitis 
 
Recurrent oral ulcerations 
 
Papular pruritic eruptions 
 
Seborrhoeic dermatitis 
 
Fungal nail infections 
 
Performance scale 2: Symptomatic, normal activity. 
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Clinical stage III 
 
Unexplained severe weight loss (over 10% of presumed or measured body 
weight) 
 
Unexplained chronic diarrhoea for longer than 1 month 
 
Unexplained persistent fever (intermittent or constant for longer than 1 month) 
 
Persistent oral candidiasis 
 
Oral hairy leukoplakia 
 
Pulmonary tuberculosis 
 
Severe bacterial infections (e.g. pneumonia, empyema, meningitis, pyomyositis, 
bone or joint infection, bacteremia, severe pelvic inflammatory disease) 
 
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
 
Unexplained anaemia (below 8 g/dl ), neutropenia (below 0.5 x 10
9
/l) and/or 
chronic thrombocytopenia (below 50 x 10
9
/l)  
 
Performance Scale 3: bed ridden for <50% of day in last one month. 
 
Clinical stage IV 
 
HIV wasting syndrome 
 
Pneumocystis jiroveci pneumonia 
 
Recurrent severe bacterial pneumonia 
 
Chronic herpes simplex infection (orolabial, genital or anorectal of more than 1 
month’s duration or visceral at any site) 
 
Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) 
[34] 
 
 
Extrapulmonary tuberculosis 
 
Kaposi sarcoma 
 
Cytomegalovirus disease (retinitis or infection of other organs, excluding liver, 
spleen and lymph nodes) 
 
Central nervous system toxoplasmosis 
 
HIV encephalopathy 
 
Extrapulmonary cryptococcosis including meningitis 
 
Disseminated nontuberculous mycobacteria infection 
 
Progressive multifocal leukoencephalopathy 
 
Chronic cryptosporidiosis 
 
Chronic isosporiasis 
 
Disseminated mycosis (histoplasmosis, coccidiomycosis) 
 
Recurrent septicaemia (including nontyphoidal Salmonella) 
 
Lymphoma (cerebral or B cell non-Hodgkin) 
 
Invasive cervical carcinoma 
 
Atypical disseminated leishmaniasis 
 
Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy 
 
Performance scale 4: Bed ridden for >50% of day in last one month. 
(Source: Revised WHO clinical staging and immunological classification of 
HIV and case definition of HIV for surveillance 2006) 
[35] 
 
STATISTICAL ANALYSIS 
                                     
                                     
Statistical analysis was carried out for 100 PLHAs after categorizing each 
variable- Age , sex ,duration of HIV, ART intake, platelet count, PT, aPTT, 
fibrinogen, LDH, CD4 count and clinical staging. Datas were  analysed using 
Statistical package- SPSS software version 11.5.The values are presented as 
mean, standard error of mean, standard deviation, standard error of mean and 
median. Percentages were used to describe the proportions of discrete variables. 
The significance of difference between the proportions was indicated by the chi-
square (x2) statistic. The significance of difference in mean between the groups 
was calculated   by   student   t-test.   Variables   were  considered  to be 
significant if P<0.05. Intervariate analysis was done by using Pearson’s r- value 
correlation. 
 
 
[36] 
 
OBSERVATIONS 
                                       
100 PLHAs were included in the study irrespective of their ART status. 
They were investigated for platelet count, prothrombin time, activated partial 
thromboplastin time, mixing studies(if required),plasma fibrinogen, serum 
lactate dehydrogenase,CD4 count and some special investigations like lupus 
anticoagulant, bone marrow studies, D-Dimer were done when required. The 
observations of the study are as noted below: 
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AGE DISTRIBUTION 
Table no.1 
 
AGE GROUP (years) n % 
 11 to 20 1 1 
 21 to 30 18 18 
 31 to 40 51 51 
 41 to 50 24 24 
 51 to 60 3 3 
 61 to 70 3 3 
  
 
The mean age was found to be 
37.96 years + 8.795. 
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SEX DISTRIBUTION 
 
Table no.2 
 
AGE GROUP (years) 
             n 
TOTAL MALE FEMALE 
    
 11 to 20 1 0 1 
21 to 30 7 11 18 
31 to 40 32 19 51 
41 to 50 16 8 24 
51 to 60 2 1 3 
61 to 70 3 0 3 
Total 61 39 100 
 
 
 
DURATION OF HIV  
No. of newly detected HIV patients(duration-0 months)-34 
Mean HIV duration was 22.16 months + 30.923 
75% patients had HIV duration <25 months 
Table no.3 
          n 
 PRE-ART 50 
 ART 50 
 
    
 
MODE OF TRANSMISSION: 
Table no.4 
 n 
SEXUAL 99 
VERTICAL 1 
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CLINICAL FEATURES AT PRESENTATION 
Table no.5 
 
 
 
 
 
 
 
 
Most of the patients (60%)  had significant co-morbid illness at presentation. 
GIT and CNS manifestations were the common presentations in our study. 
Chart showing the distribution of significant comorbid illnesses 
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Table no.6 
     
Present 
THROMBOSIS           8 
BLEEDING           1 
  
Among the hemostatic manifestations, thrombosis was much more frequent than 
bleeding. Infact, bleeding in the form of hematochezia occurred only in one 
patient and in that case also, cause was haemorrhoids rather than due to altered 
hemostasis. 
Thrombotic manifestations in the form of  six  cases of  ischemic stroke, one 
deep vein thrombosis and one cavernous sinus thrombosis. 
 
Table no.7 
 Pre-ART On  ART Total 
n % n % N 
Thrombosis 7 87.5 1 12.5 8 
 
 
 
COINFECTION WITH VIRAL HEPATITIS 
Table no.8 
             
n 
           HbsAg +ve 4 
AntiHCV +ve 2 
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CD4 COUNT DISTRIBUTION 
Table no.9 
CD4 COUNT(cells/mm3) n % 
<100 24 24 
101 to 200 19 19 
201 to 300 9 9 
301 to 400 19 19 
401 to 500 10 10 
>500 19 19 
  
 
The mean CD4 count in our study was 306.69 cells/mm
3 
 
And the median was 267.Most of our patients (43%) had CD4 count < 200. 
 
 
Chart showing the distribution of CD4 count 
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WHO STAGING DISTRIBUTION 
Table no.10 
 
WHO CLINICAL STAGING n % 
 I 40 40% 
 II 4 4% 
 III 17 17% 
 IV 39 39% 
  
 
Majority of our patients were in extremes-stage I & IV as we had equal number 
of out-patients (most of whom were asymptomatic belonging to stage I) and in-
patients(who had significant comorbid illnesses and AIDS defining conditions). 
 
Chart showing the distribution of  WHO staging 
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PLATELET COUNT DISTRIBUTION 
Table no.11 
PLATELET COUNT(lakh cells/mm3) n % 
<1 10 10% 
1 to 1.5 41 41% 
1.51 to 2.0 31 31% 
>2 18 18% 
 
The mean platelet count was 1.64 lakhs/mm
3 
+ 0.8431 with the majority falling 
in the range of 1-1.5lakhs/mm
3
.Median was 1.50 lakhs/mm
3
. 
Thrombocytopenia(<1.5 lakhs/mm
3
) was found in 51%. 
 
Chart showing the distribution of platelet count 
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    Thrombocytopenia      n       % 
Mild       (1-1.5lakhs)     41       41 
Moderate  (0.5-1lakh)      9        9 
Severe        (<50,000)      1        1 
[44] 
 
THROMBOCYTOPENIA vs WHO STAGING 
Table no.13 
 
THROMBOCYTOPENIA 
                        WHO  STAGES 
I II III           IV 
Mild         (1-1.5lakhs) 17(41.46%) 2(4.87%) 9(21.95%) 13(31.7%) 
Moderate (0.5-1lakh)  - 2(22.23%) 1(11.12%) 6(66.67%) 
Severe       (<50,000) - - -  1(100%) 
 
In our study, majority of thrombocytopenia noted in stages I & IV. There was 
no statistical significance between thrombocytopenia and WHO staging (p 
value-0.066).  
 
THROMBOCYTOPENIA vs CD4 COUNT 
Table no.14 
CD4 
COUNT(cells/mm3) 
THROMBOCYTOPENIA 
Mild 
(1-1.5lakhs) 
Moderate 
(0.5-1lakh) 
Severe 
(<0.5lakh) 
< 100 9(21.95%) 4(44.44%) 1(100%) 
101 to 200 5(12.19%) 1(11.11%) - 
201 to 300 4(9.75%) - - 
301 to 400 11(26.82%) 2(22.22%) - 
401 to 500 4(9.75%) - - 
>500 8(19.51%) 2(22.22%) - 
 
Mild cases of thrombocytopenia were distributed evenly in all ranges of CD4 
count, but still almost 66% cases were reported in patients with CD4 count >200 
cells/mm
3
.On the other hand, moderate and severe thrombocytopenia were 
noted in patients with CD4 count <200cells/mm
3
.There was no statistical 
significance between CD4 count and thrombocytopenia (p value-0.663). 
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THROMBOCYTOPENIA vs COMORBID ILLNESS 
Table no.15 
 
 
 
 
 
 
Majority of patients with thrombocytopenia had significant comorbid illness at 
presentation. But still mild thrombocytopenia could be noted among PLHAs 
without significant illness. There was no statistical significance between 
thrombocytopenia and presence of comorbid illness (p value-0.135). 
 
THROMBOCYTOPENIA vs AGE DISTRIBUTION 
Table no.16 
AGE GROUP (years) 
THROMBOCYTOPENIA  
     n 
 
% Mild Moderate Severe 
11 to 20 
- 1 - 1 1.96 
21 to 30 
8 2 - 10 19.60 
31 to 40 
20 5 1 26 50.98 
41 to 50 
10 - - 10 19.60 
51 to 60 
1 1 - 2 3.92 
61 to 70 
2 - - 2 3.92 
 
 
 
 
 
THROMBOCYTOPENIA 
SIGNIFICANT  COMORBID    
        ILLNESS                                                           
 
PRESENT 
           
ABSENT 
 
 Mild(1-1.5 lakhs) 24(58.53%) 17(41.46%) 
 Moderate(0.5-1 lakh) 9(100%)      - 
Severe(<50,000) 1(100%)      - 
[46] 
 
PROTHROMBIN TIME: 
Table no.17 
PROTHROMBIN TIME       n % 
Normal 48 48 
Prolonged 48 48 
Reduced 4 4 
 
Mean PT was 13.52 seconds + 2.347.Median was 13 seconds. 
 
PROTHROMBIN TIME vs WHO STAGING 
Table no.18 
 
PROTHROMBIN 
TIME 
                 WHO STAGING 
I II III IV 
Normal 26 1 9 12 
Prolonged 11(22.91%) 2(4.16%) 9(18.75%) 26(54.16%) 
Reduced 3 1 - - 
 
Majority of prolonged PT was noted in patients with stage IV disease. There 
was statistical significance for PT with WHO staging (p value-0.015) by Chi 
square test. 
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PROTHROMBIN TIME vs CD4 COUNT 
Table no.19 
 
CD4 
COUNT(cells/mm3) 
PROTHROMBIN TIME 
Normal Prolonged Reduced 
< 100 10 14(29.16%) - 
101 to 200 12 7(14.58%) - 
201 to 300 5 4(8.33%) - 
301 to 400 9 9(18.75%) 1 
401 to 500 5 3(6.25%) 2 
>500 7 11(22.91%) 1 
 
There was no statistical significance between CD4 count and  PT (p value-
0.114) by Chi square test. 
 
PROTHROMBIN TIME vs COMORBID ILLNESS 
Table no.20 
 
 
PROTHROMBIN TIME 
SIGNIFICANT COMORBID        
ILLNESS 
 
PRESENT 
           
ABSENT 
 
               Normal 22 26 
           Prolonged 37(77.08%) 11(22.91%) 
             Reduced 2 - 
 
Majority of patients with prolonged PT (77%)  had significant comorbid illness. 
There was statistical significance between PT and co-morbid illness (p value-
0.006) by Chi square test. 
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ACTIVATED PARTIAL THROMBOPLASTIN TIME 
Table no.21 
 
ACTIVATED PARTIAL 
THROMBOPLASTIN 
TIME 
n % 
Normal 72 72% 
Prolonged 22 22% 
Reduced 6 6% 
 
Mean was 34.978 seconds + 10.153.Median was 32 seconds. 
 
aPTT vs WHO STAGING 
Table no.22 
 
   aPTT 
          WHO STAGING 
       I       II III IV 
Normal 35 3 12 22 
Prolonged 1(4.54%) 1(4.54%) 6(27.27%) 14(63.63%) 
Reduced 4 - - 2 
 
Majority of patients with  prolonged aPTT were noted in advanced stages III 
and  IV disease. There was statistical significance for aPTT with WHO 
staging(p value-0.008). 
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aPTT vs CD4 COUNT 
Table no.23 
CD4 
COUNT(cells/mm3) 
aPTT 
Normal Prolonged Reduced 
< 100 17 7(31.81%)          - 
101 to 200 17 2(9.09%) - 
201 to 300 7 2(9.09%) - 
301 to 400 12 5(22.72%) 2 
401 to 500 6 2(9.09%) 2 
>500 13 4(18.18%) 2 
 
There was no statistical significance between CD4 count and  aPTT (p value-
0.339) by Chi square test. 
 
aPTT vs COMORBID ILLNESS 
Table no.24 
 
ACTIVATED 
PARTIAL 
THROMBOPLASTIN 
TIME 
SIGNIFICANT COMORBID   
ILLNESS                                                           
 
PRESENT 
           
ABSENT 
 
 Normal 37 35 
 Prolonged 21(95.45%) 1(4.55%) 
 Reduced 3 3 
 
Almost all except one patient with prolonged aPTT had significant comorbid 
illness. There was statistical significance between aPTT and comorbid illness (p 
value-0.001) by Chi square test. 
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PLASMA FIBRINOGEN: 
Table no.25 
PLASMA FIBRINOGEN(mg/dl) 
                  
n % 
<180    36 
 
36 
180-350 60 60 
>350 4 4 
 
 
Our lab normal plasma fibrinogen level-180 to 350 mg/dl. 
Most of our patients (60%) had normal fibrinogen level in plasma. 
Mean was 198.27 + 70.295.Median was 193. 
Level was decreased in 36 cases and increased in 4. 
 
Chart showing the distribution of plasma fibrinogen 
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FIBRINOGEN vs WHO STAGING 
Table no.26 
 
FIBRINOGEN               WHO STAGING 
 I II III IV 
Normal 25 2 8 16 
Increased - - 1(25%) 3(75%) 
Reduced 7(19.44%) 2(5.55%) 9(25%) 18(50%) 
 
Majority of fibrinogen derangements are noted among advanced stages. There 
was statistical significance between fibrinogen and  WHO staging (p value-
0.018) by Chi square test. 
 
FIBRINOGEN vs CD4 COUNT 
Table no.27 
CD4 
COUNT(cells/mm3) 
FIBRINOGEN 
Normal Increased Reduced 
< 100 9 2(50%) 13(36.11%) 
101 to 200 14 - 5(13.88%) 
201 to 300 7 - 2(5.55%) 
301 to 400 8 2(50%) 9(25%) 
401 to 500 9 - 1(2.77%) 
>500 13 - 6(16.66%) 
 
Almost 50% of PLHAs with reduced fibrinogen level had CD4 count <200 
cells/mm
3
. There was no statistical significance between fibrinogen and CD4 
count (p value-0.072) by Chi square test. 
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FIBRINOGEN vs COMORBID ILLNESS 
Table no.28 
 
 
 
FIBRINOGEN 
SIGNIFICANT COMORBID                                                                                                                 
ILLNESS 
 
PRESENT 
           
ABSENT 
 
          Normal 28 27 
         Increased 4(100%) - 
          Reduced 29(80.55%) 7(19.44%) 
  
Majority of patients with fibrinogen derangements had significant comorbid 
illness. There was statistical significance between fibrinogen and comorbid 
illness (p value-0.001) by Chi square test. 
 
SERUM LACTATE DEHYDROGENASE 
Table no. 29 
 
SERUM  LDH(U/L) N % 
<200 37 37 
200-400 55 55 
>400 8 8 
 
 
Our lab normal reference range for LDH was 200-400U/L. 
Mean was 257.12 + 128.25.Median was 223U/L. 
Majority had normal LDH (55%)  or  reduced LDH (37%).  
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Chart showing the distribution of serum LDH 
 
  
LDH vs WHO STAGING 
Table no.30 
 
LDH(U/L) 
                            WHO STAGING 
I II III IV 
Normal 21 2 11 21 
Increased - 1(12.5%) 1(12.5%) 6(75%) 
Reduced 19 1 6 11 
 
About 75% of patients with raised LDH belonged to stage IV. There was  
statistical significance between WHO staging and  LDH(p value-0.005) by 
student t test. 
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LDH vs CD4 COUNT 
Table no.31 
CD4 
COUNT(cells/mm3) 
LDH 
Normal Increased Reduced 
< 100 16 3(37.5%) 5 
101 to 200 8 - 11 
201 to 300 5 - 4 
301 to 400 9 3(37.5%) 7 
401 to 500 6 - 4 
>500 11 2(25%) 6 
 
LDH was distributed in CD4 count of all varied ranges. There was no statistical 
significance between LDH and CD4 count (p value-0.363) by Chi square test. 
 
LDH vs COMORBID ILLNESS 
Table no.32 
SERUM LDH SIGNIFICANT COMORBID 
ILLNESS 
Present Absent 
Normal 35 18 
Increased 8(100%) - 
Reduced 18 14 
 
All patients with increased LDH had significant comorbid illness. There was 
statistical significance between LDH and comorbid illness (p value-0.022) by 
Chi square test. 
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STATISTICAL ANALYSIS 
(student t test) 
 
Analysis of hemostatic parameters between patients on ART & non-ART 
       PRE-ART        ART  
P 
value 
Mean SD Mean SD 
Platelet 1.76 1.08 1.52 0.47 0.156 
PT 13.93 2.68 13.1 1.89 0.077 
aPTT 35.5 10.29 33.5 7.72 0.281 
Fibrinogen 203.53 85.58 193.02 51.02 0.458 
LDH 250.12 116.95 264.12 139.47 0.588 
 
The above analysis shows that there is no statistical significance between 
hemostatic parameters  of  patients on ART & without ART. 
 
Analysis of hemostatic parameters with WHO staging 
 
Parameters STAGE I STAGE II STAGE III STAGE IV P 
value 
Mean SD Mean SD Mean SD Mean SD 
Platelet 1.67 0.44 0.97 0.28 1.62 0.64 1.67 1.2 0.455 
PT 12.39 1.33 12.27 1.7 14.2 2.07 14.49 2.8 0.000 
aPTT 29.67 4.4 33.42 4.28 38.08 10.09 38.14 10.48 0.000 
LDH 219.3 46.17 422.2 361.8 241.8 99.45 286.8 145.2 0.005 
 
From the above analysis, it is shown that there is statistical significance of  PT, 
aPTT, LDH with WHO staging. 
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Analysis of  hemostatic parameters with CD4 count 
 
Parameters  CD4 count 
P value 
Platelet 1 
PT 0.257 
aPTT 0.194 
Fibrinogen 0.291 
LDH 0.233 
 
The above analysis shows no statistical significance between hemostatic 
parameters and CD4 count. 
 
Analysis of hemostatic parameters with ART duration 
  
Parameters 
 
 
ART 
duration  
P value 
Platelet 0.853 
PT 0.369 
aPTT 0.225 
Fibrinogen 0.370 
LDH 0.712 
 
There was no statistical significance between hemostatic parameters and ART 
duration. 
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                                            CORRELATIONS 
(Pearson method) 
 
Hemostatic parameters vs ART duration 
  
 
Parameters 
           ART duration 
Pearson 
correlation 
coefficient 
 
 P value 
Platelet 0.015 0.920 
PT 0.124 0.391 
aPTT -0.055 0.706 
Fibrinogen -0.060 0.681 
LDH -0.053 0.717 
 
 
Hemostatic parameters vs HIV duration 
 
 
Parameters 
              HIV  duration 
Pearson 
correlation 
coefficient 
 
P value 
Platelet -0.148 0.141 
PT -0.026 0.797 
aPTT -0.062 0.539 
Fibrinogen -0.174 0.083 
LDH   0.173 0.085 
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Hemostatic parmeters vs CD4 count 
 
 
Parameters 
               CD4 count 
Pearson 
correlation 
coefficient 
 
P value 
Platelet 0.049 0.630 
PT -0.137 0.174 
aPTT -0.069 0.497 
Fibrinogen 0.000 0.997 
LDH 0.091 0.368 
 
From the above correlations analysis, there was no correlation found between 
hemostatic parameters and HIV duration, ART duration and CD4 count. 
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DISCUSSION 
                                         
It is well appreciated that PLHA’s irrespective of their ART status 
presents with many systemic disturbances including hemostatic derangements. 
However, not all these abnormalities are reflected clinically. Studies pertaining 
to hemostatic changes in PLHA’s are only few throughout the world and in 
India, there was only one study
73 
(BMC Blood Disorders 2009, 9:5 ) which 
included coagulation parameters also as a part of haematological manifestations. 
The observation made in the PLHAs with respect to platelet count, prothrombin 
time, activated partial thromboplastin time, plasma fibrinogen, serum lactate 
dehydrogenase, CD4 count and WHO stages were analysed and the following 
inferences were drawn. 
AGE DISTRIBUTION 
The mean age of the study population was 37.96 years+8.795. About 
51% of them were in age group of 30-40 years. As per the data released by 
Tamil Nadu State AIDS control society (TANSACS) about 50% of HIV 
infected patients belonged to 30 - 49 years at the time of diagnosis 
(70)
.In the 
western countries about 36% of them were in the 35-44 years age group at the 
time of diagnosis, which happens to be the major age group affected 
(71)
.Our 
data is in accordance with these data. 
[60] 
 
 
SEX DISTRIBUTION 
In our study population,61% were males and 39% were females. The 
male to female ratio was approximately 3:2 The sex ratio of PLHA is at the time 
of diagnosis was 8:3 in India
70
 and 7:3 in western countries
71
.The increased 
female representation in our study is probably a more disciplined followup 
observed among women in the outpatient clinic. 
                  WHO STAGE DISTRIBUTION 
Most of the PLHA’s were in extremes in stages I (40%) and IV 
(39%).This is because our study comprised equal number of  inpatients(who 
were admitted in ward with significant comorbid illnesses) and out 
patients(mostly asymptomatic attending ART op).  
CD4 COUNT DISTRIBUTION 
In our study, the mean CD4 count was 306.69 cells/mm
3 
+237.95 and 
median was 267 cells/mm
3
.It ranged from 21 to 1247 cells/mm
3
. Since our 
study comprised of PLHA’s in extremes of stages, we had equal distribution of 
patients in CD4 counts of varied ranges. 43% of  PLHA’s in our study had CD4 
count<200 cells/mm
3
 and the rest had CD4 count >200 cells/mm
3
. 
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THROMBOCYTOPENIA 
Mean platelet count in our study was 1.64 +0.84 lakhs/mm
3 
and median 
was 1.50 lakhs/mm
3
.It ranged from 30,000 to 7.42 
lakhs/mm
3
.Thrombocytopenia (<1.5 lakhs/mm
3) was found in 51% of PLHA’s 
in our study. 
Mild thrombocytopenia(1-1.5 lakhs/mm
3)was found in 41 PLHA’s 
,majority of whom were in either stage I(41%) or in stage IV(31%).They were 
distributed in CD4 count of all varied ranges. Majority of them had significant 
co-morbid illness(58.5%) in the form of viral or alcoholic hepatitis, acute febrile 
illnesses and infections(pulmonary or meningeal TB, splenic candidiasis, 
splenic abscess, sepsis and cellulitis). However few were asymptomatic 
(41.46%) falling under stage I which signifies the varied mechanisms attributed 
to HIV related thrombocytopenia and its early occurrence in the course
10 
. 
Among PLHA’s with moderate and severe thrombocytopenia, most 
(67%) of them belonged to advanced stage (stage IV).CD4 count didn’t 
correlate with the severity of thrombocytopenia. All had significant co-morbid 
illness in the form of stroke, infections(TB, Cryptococcal meningitis, sepsis) 
and viral hepatitis. Four patients with moderate to severe thrombocytopenia had 
thrombotic manifestations-three with ischemic stroke and one with cavernous 
sinus thrombosis. None had bleeding manifestations. 
[62] 
 
West Indian Med J. 2009 Nov; 58(5):437-40  concluded that among the 
HIV-infected patients, platelet count did not differ significantly (p > 0.05) 
between those with CD4 count < 200 cells//L and those with CD4 count>200 
cells/microL. In our study also, there was neither statistical significance (P 
value=1) nor correlation(P value=0.63) between platelet count and CD4 count.
72 
Two previous Indian studies-BMC Blood Disorders 2009, 9:5 & Turk J 
Hematol 2008, 25:13-9 also found no significant correlation between 
thrombocytopenia and CD4 count.
73,74 
PROTHROMBIN TIME 
Prothrombin time was prolonged in 48% of our study population with the 
mean PT of 13.52+2.347 seconds. Median was 13 seconds. Majority of patients 
with prolonged PT belonged to advanced stage IV (54%).There was statistical 
significance between PT and WHO staging (P value-0.000).However, the CD4 
count didn’t correlate well as PT was prolonged in PLHA’s with CD4 count of 
all ranges. Majority were males (72.91%) suggesting the possible role of 
alcoholism deranging the PT. About 77% of PLHA’s with prolonged PT had 
significant co-morbid illness in the form of liver disease, pancreatitis, diarrheal 
diseases, acute febrile illnesses, infections(TB, Candidiasis, Cryptococci, 
sepsis), stroke, venous thrombosis and malignancy(carcinoma cervix). All the 
patients with viral co-infection had prolonged PT(4 were HbsAg+ and 2 were 
anti-HCV+). However 11 patients with prolonged  PT didn’t have any 
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significant illness at presentation and they all were grouped under stage I. This 
signifies that PT prolongation can occur in any stage of HIV infection and 
usually asymptomatic. With mixing studies, most of the prolonged PT got 
corrected which reveals the possible clotting factor deficiencies in HIV 
infection and its associated co-morbid illnesses. Few patients in whom 
prolongation of  PT was not corrected fully, was probably due to chronic 
subclinical consumption coagulopathy or acquired inhibitors. 
ACTIVATED PARTIAL THROMBOPLASTIN TIME 
Among the 100 PLHA’s analysed, 22 had prolonged aPTT with the mean 
of 34.978 seconds+10.153. Median was 32 seconds. Majority of 
patients(63.63%) with prolongation of aPTT were in advanced stage IV. There 
was statistical significance between aPTT and WHO staging (P 
value=0.000).Except one, all had significant co-morbid illnesses in the form of 
liver disease, stroke, ARDS, febrile illnesses and infections(TB, Cryptococci, 
Candidiasis, sepsis). None had bleeding manifestations. Three patients with 
prolonged aPTT had thrombotic manifestations in the form of ischemic stroke. 
Among those 3 patients, one had associated HCV co-infection which might 
have contributed to hypercoagulability in addition to factors contributed by HIV 
infection.  
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PROLONGED PROTHROMBIN TIME & aPTT 
Among the 100 PLHA’s, 20 had prolongation of both PT and aPTT. 
Majority of patients were in advanced stages IV (65%) and III(30%). All(95%) 
except one  had significant co-morbid illnesses in the form of liver disease, 
stroke, chronic diarrhea, febrile illnesses and infections(TB, Cryptococci, 
sepsis). None had bleeding manifestations. Two had thrombotic manifestations 
in the form of stroke. Five patients with prolonged PT and aPTT had viral co-
infection(3 HbsAg +, 2 anti-HCV +).   
West Indian med. j. vol.58 no.5 Mona Nov. 2009 published a study 
done by  R Omoregie et al among HIV patients in Benin City, Nigeria 
which concluded that PT and APTT are higher in HIV patients with CD4 count 
< 200 cells/µL, but only PT correlates with CD4 count and the correlation was 
observed only in HIV patients with CD4 count < 200 cells/µL. This study 
excluded symptomatic PLHA’s. Endothelial activation is suggested as the cause 
of the coagulation defect.
72
 But in our study done among Indian population 
there was no correlation of CD4 count with any of hemostatic parameters 
including PT as we included significant number of symptomatic patients. 
In the study conducted in PGIMER, Chandigarh on Profile of 
hematological abnormalities in Indian HIV infected individuals, there was 
no coagulation abnormalities detected.
73
 This was in contrast to our study done 
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among Tamil Nadu patients where much of derangements of coagulation profile 
could be noted.  
PLASMA FIBRINOGEN 
Among the 100 PLHA’s analysed in our study, 40% had fibrinogen 
derangements out of normal range. 36 patients had reduced fibrinogen levels 
while 4 had raised fibrinogen level in plasma. Mean was 198.27+70.295 mg/dl. 
Median was 193mg/dl.19 of 36 patients with reduced fibrinogen were on ART. 
So, the significant number of patients with reduced fibrinogen level in our study 
probably reflects the use of NNRTIs as the first line therapy for newly 
diagnosed PLHAs. Erin Madden et al79 -AIDS 2008;22(6):707-715- 
concluded that  Protease inhibitor use is associated with elevated fibrinogen 
levels which may contribute to increased risk of atherosclerosis in HIV-infected 
patients. Conversely, NNRTI use is associated with lower fibrinogen levels 
which may decrease risk of atherosclerosis.  
The increase in fibrinogen noted in 4 PLHAs could be attributed to its 
response as an acute phase reactant as all these patients had significant co-
morbid illness. Most of the fibrinogen derangements had occurred in advanced 
stage IV. Almost 50% of our cases with reduced fibrinogen level had CD4 
count <200 cells/mm
3. Among the PLHA’s with reduced fibrinogen, about 81% 
had significant co-morbid illnesses in the form of stroke, liver disease, 
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malignancy (Ca cervix) and infections (TB, Candidiasis, Cryptococci, 
pneumonia, sepsis). Five patients with reduced fibrinogen had thrombotic 
manifestations. All the four patients with increased fibrinogen had significant 
co-morbid illnesses and two had stroke among them. 
SERUM LACTATE DEHYDROGENASE 
Only eight of our patients had raised LDH. Mean LDH for our 100 cases 
was 257.12+128.25 U/L. Median was 223U/L. About 75% of patients with 
raised LDH belonged to stage IV. All the patients with raised LDH had 
significant co-morbid illnesses in the form of TB, ARDS, Hepatitis and 
malignancy (Carcinoma cervix). There was statistical significance for LDH with 
WHO staging (P value=0.005).The increased LDH could be attributed to 
microangiopathic haemolysis in 2 cases (malignancy,  RHD),  hepatitis 
(alcoholic)  in  a  case  and  hemophagocytic  histiocytosis with pancytopenia in 
a young boy with vertically transmitted HIV.The haemophagocytosis was made 
detected in the bone marrow. 
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THROMBOTIC EVENTS 
In our study population of 100 PLHA’s irrespective of their ART status, 
we noted eight(8%) patients with thrombotic events in the form of  arterial 
thrombosis(ischemic stroke) as well as venous thrombosis(deep venous 
thrombosis and cavernous sinus thrombosis).Thrombosis and a 
Hypercoagulable State in HIV-Infected Patients-Yu-Min P. Shen et al –also 
gave an incidence of thromboembolic events ranging from 0.26 to 7.6%.
75
 All 
the eight patients were ambulatory and had no known risk factors for pathologic 
thrombus formation.  
On analysis of their clinical as well as hemostatic profile, we made the 
following observations: 
 1) Mean age was 39.125+11.85 years. Median was 37.5 years. It ranged from 
27 to 65 years. This shows that thrombotic events are common in younger 
PLHA’s suggestive of  a probable hypercoagulable state. This age group 
correlated with the article- Stroke in HIV infection and AIDS- Dobbs and 
Berger-which  also  determined the increased risk of stroke to be most apparent 
in the young HIV-infected population in whom other risk factors for stroke are 
seldom evident
76
. Mechanisms underlying the increased risk include 
opportunistic infectious meningitides and vasculitides, primary HIV 
vasculopathy, altered coagulation and cardioembolic events, although the cause 
may be multifactorial or remain cryptic. 
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2) Seven of them were males and one was female. 
3) Mean duration of HIV was 6.5+10.88 months. Five of them were newly 
detected as positive for HIV serology with this presentation suggesting that 
thrombotic manifestation may be the initial presentation of  HIV  infection 
itself.  
4) Only one was on ART for 12 months duration with first line regimen-
zidovudine, lamivudine and nevirapine therapy.  
5) The mode of transmission was heterosexual in all the patients. 
6) None had bleeding manifestations. 
7) Among the eight cases, six presented as ischemic stroke, one as deep venous 
thrombosis of upper limb and one as cavernous sinus thrombosis. On analysing 
the six cases of stroke, five presented as young stroke with age <40 years. Lipid 
profile of all the patients with stroke were within normal limits. One had 
positive serology for Hepatitis C virus and all others didn’t have any co-morbid 
illnesses  other than the modifiable risk factors like smoking and alcoholism. 
8) Their renal and liver function tests were normal except the one with anti-
HCV positivity who had raised bilirubin and liver enzymes. 
9) Mean haemoglobin was 10.45+2.769 gms/dl. It ranged from 6.6 to 14.8 
gms/dl with the median of 10.2. 
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10) Mean platelet count was 1.94+2.29lakhs/mm
3
.Median was 1.23 with the 
range from 0.30 to 7.42 lakhs/mm
3
. Four had thrombocytopenia of whom three 
presented as ischemic stroke and one had cavernous sinus thrombosis. 
11) Two had isolated prolongation of prothrombin time and one with isolated 
prolongation of aPTT. Two others had prolongation of both PT and aPTT. 
12) Among the eight PLHA’s with thrombosis, seven had fibrinogen 
derangements: 5 with reduced level and 2 with increased fibrinogen level. Mean 
was 205.15+153.67 mg/dl. Median was 155.50 with the range from 57.2 to 
484mg/dl. Among the six patients with stroke, 4 had reduced fibrinogen while 2 
had increased level. 
13) Mean LDH level was 231.5+ 64.78 U/L. Median was 203 with the range 
from 163 to 314 U/L. 
14) Mean CD4 count was 179.375+172.30 cells/mm
3
.Median was 97 with the 
range from 85 to 563 cells/mm
3
.Six had CD4 count <200cells/mm
3
, suggesting 
the occurrence of thrombotic manifestations with severe immunosuppression. 
15) All the eight patients belonged to WHO clinical stage IV. 
16) Special investigations like D-Dimer and LAC in seven patients with 
thrombosis excluding that elderly male with stroke. LAC was positive only in 
one patient and D-Dimer was significantly elevated in 3 patients.  
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INTERESTING CASES 
We analysed few interesting cases and did some relevant special 
investigations. 
 A 36 yr old male PLHA on irregular ART presented with ischemic stroke 
& severe thrombocytopenia whose PT, aPTT was also prolonged which 
with mixing studies showed delayed type inhibitor.LAC was also done 
which turned to be positive. Bone marrow was normocellular with normal 
megakaryocytes and erythropoiesis. 
  Marrow was also done for a young boy with vertically transmitted HIV 
who presented with pancytopenia. The marrow was hypocellular  with 
dimorphic erythropoiesis and normal myeloid maturation. 
Megakaryocytes were adequate with hyperlobulated forms and 
megakaryocyte bare nuclei. Mild Lymphocytosis 6% with few atypical 
cells and increased iron stores(2+) with no sideroblasts seen. 
Hemophagocytosis+. Viral serology for hepatotropic viruses and TORCH 
infection were negative. So we attribute the pancytopenia to ART 
therapy(zidovudine induced with probable superadded viral infection). 
 Another 27 yr old male who presented as young stroke had moderate 
thrombocytopenia with elevated fibrinogen, normal D-Dimer and 
negative LAC. Two other young PLHA’s with ischemic stroke had 
reduced fibrinogen with normal platelet count and D-Dimer and negative 
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LAC. PT and aPTT were also normal in all these three patients. So this 
directs us towards the possible HIV associated vasculopathy. Mu et al.: 
Update on HIV-associated Vascular Diseases-analysed the profound 
functional alterations of the endothelium in HIV infection through 
various clinical and laboratory studies. The virus and its viral proteins 
such as gp120, Tat, and Nef are able to induce expression of several 
adhesion molecules and inflammatory cytokines such as ICAM-
1,VCAM-1, E-selectin, TNF-alpha and IL-6. Leukocyte adherence to the 
endothelium is enhanced as the expression of these cell adhesion 
molecules increases. Elevated circulating levels of vWF, a glycoprotein 
facilitating platelet adhesion, synthesized in endothelial cells and 
inflammatory cells, are elevated and correlate to circulating levels of 
inflammatory cytokines. A hypercoagulable state is induced depending 
on plasma HIV load. In addition, HIV and its viral proteins can also 
induce endothelial apoptosis and increase endothelial permeability. These 
effects could significantly contribute to vascular disease formation. 
However, the molecular mechanisms underlying HIV associated vascular 
diseases and endothelial injury are not completely understood.
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 Another young patient with sepsis and cavernous sinus thrombosis had 
elevated D-Dimer with much reduced fibrinogen suggestive of DIC and 
he ultimately succumbed to his illness. Another patient with ischemic 
stroke and Hepatitis C Virus co-infection also had elevated D-Dimer with 
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much reduced fibrinogen and who also expired. Both the patients were 
not on ART. This proved D-Dimer elevation as an important marker for  
all cause mortality in PLHAs.
10 Inflammatory and Coagulation 
Biomarkers and Mortality in Patients with HIV Infection-Lewis H. 
Kuller for the INSIGHT SMART Study Group concluded that IL-6 
and D-Dimer were strongly related to all-cause mortality. Interrupting 
ART may further increase the risk of death by raising  IL-6 and D-Dimer 
levels. They also hypothesized that increased HIV-RNA levels following 
ART interruption induced activation of tissue factor pathways, 
thrombosis, and fibrinolysis. Therapies that reduce the inflammatory 
response to HIV and decrease IL-6 and D-Dimer levels may warrant 
investigation.
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SUMMARY AND CONCLUSION 
Our study included 100 patients positive for HIV ELISA- 50 outpatients 
and 50 inpatients. 50 patients were on ART and 50 were pre-ART. The 
hemostatic parameters were evaluated in all individuals irrespective of their 
clinical symptoms. 
Thrombocytopenia was noted among 51 PLHA’s in our study but there 
was no statistically significant correlation with either CD4 count or WHO 
staging of disease. Significant comorbid illnesses were identified in all PLHA’s 
with moderate-severe thrombocytopenia and 58.5% of PLHA’s with mild 
thrombocytopenia. The thrombocytopenia in otherwise asymptomatic patients 
might be attributed to HIV infection itself or due to drugs. 
Prothrombin time was prolonged in 48% patients in our study and aPTT 
in 22% of our patients. The higher incidence of PT prolongation could be 
attributed to alcoholic hepatic dysfunction. All patients with aPTT prolongation 
had significant comorbid illnesses. The increased coagulation parameters got 
corrected with normal plasma except the one who presented with stroke and 
found to be positive for LAC. 
The most interesting feature noted in our study was the striking absence 
of bleeding diathesis despite the hemostatic derangements. But thrombotic 
manifestations were noted in eight patients in the form of ischemic stroke, DVT 
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and cavernous sinus thrombosis.  This leads us to the possible influence of HIV 
infection & ART on the antithrombotic factors like protein C, protein S, anti-
thrombin III and others which needs to be distinctly delineated. Most of the 
studies have shown significant changes in the presence of antiphospholipid 
antibodies and the lupus anticoagulant; deficiencies of protein C, protein S, 
heparin cofactor II, and antithrombin; and increased levels of  von Willebrand 
factor and D-Dimer and these abnormalities correlate with the severity of HIV-
associated immunosuppression as measured by CD4+ cell counts and the 
presence of infectious or neoplastic diseases associated with HIV infection.  
The emphasis of our observation should also be on these lines, if effective 
prophylactic measures against thrombosis need to be incorporated in routine 
therapeutic strategies. This provides a strong rationale for careful prospective 
studies to evaluate the prevalence, pathogenesis, and risk factors associated with 
the development of thromboembolic complications in patients with HIV 
infection. 
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SCOPE FOR FURTHER STUDIES 
 Evaluation of    i) platelet functional studies, ii) coagulation factor assays, 
and iii) antithrombotic factor assays in PLHAs before commencing ART and 
while on treatment should be done. This could decide on the need for including 
thromboprophylaxis on HIV patients irrespective of their ART status, should 
the clinical profile suggest either virus induced or drug induced predisposition 
to thrombosis.                                                                          
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PROFORMA 
 
PRESENT HISTORY  
 
 Duration of  HIV infection 
 Duration of ART intake 
 Bleeding manifestations 
  
 PAST & PERSONAL HISTORY 
 
 Jaundice 
 Alcoholism 
 Blood Transfusion 
 Premarital/Extramarital contact 
 Homosexuality 
 Tattooing/IV drug abuse 
 Native treatment 
 Drug intake like ATT/Anti-epileptics 
 Surgeries in past 
  
In women-obstetric and menstrual history 
 
CLINICAL EXAMINATION 
 
 Anaemia 
 Jaundice 
 Pedal Oedema 
 Stigmata of Tuberculosis 
 Lymphadenopathy 
 Clubbing 
 Purpura, bleeding gums 
 Oral candidiasis 
 Glossitis 
 Herpes zoster 
 Weight 
  
VITAL SIGNS 
 
 Pulse rate 
 Blood Pressure 
 Respiratory rate 
 Temperature 
  
SYSTEMIC EXAMINATION 
 
 Cardiovascular system 
 Respiratory system  
 Abdomen examination 
 Nervous system examination 
  
  
INVESTIGATIONS  
  
 Urine analysis 
 
 Complete hemogram (including platelet count) 
 
 COAGULATION PROFILE 
                                     
                                    Prothrombin time  
                                    Activated partial thromboplastin time 
                                    Mixing studies(if PT/aPTT prolonged) 
                                    Plasma fibrinogen 
 
 Peripheral smear, reticulocyte count 
 
 Renal function tests 
 
 Liver function tests  
 
 Fasting lipid profile 
 
 Serum lactate dehydrogenase 
 
 Viral markers- HbsAg, anti-HCV 
 
  CD4 cell count 
 
 Special investigations-D-Dimer, Lupus anticoagulant, bone marrow study 
 
 ECG in all leads  
 
 Chest X ray PA view 
 
 USG-Abdomen & Pelvis  
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1 35 F 0 0 S nil Ischemic stroke 0.7 0.8 46 75 8 1.96 N N 168 198 N N 108 IV
2 26 F 24 12 S nil Guillian Barre syndrome 0.9 0.9 26 110 10.2 1.7 N N 223 243 N N 558 IV
3 37 M 18 8 S nil Vacuolar myelopathy/Pulmonary TB 0.9 0.7 19 68 7.7 1.4 P N 176 238 N N 59 IV
4 31 F 72 24 S nil TB meningitis 1 1.1 24 87 6.2 1.27 P N 218 279 N N 43 IV
5 33 M 12 0 S nil Alcoholic hepatitis 0.8 8.5 238 220 11 1.65 P P 113.4 358 N N 699 IV
6 39 M 0 0 S nil Ischemic stroke/Viral hepatitis 1 6.8 118 92 10.5 0.81 P P 78 294 N P 88 IV
7 30 F 0 0 S Bleed PR Pulmonary TB/PGL/Haemorrhoids 0.9 0.6 42 149 10.4 1.8 N N 225 139 N N 118 III
8 40 M 120 30 S nil Viral hepatitis 0.8 19 270 264 9.9 1.2 P P 88.5 271 P N 224 IV
9 33 M 0 0 S nil Persistent fever/PGL 0.8 0.8 30 82 8.3 1.9 N N 243 189 N N 214 III
10 50 M 0 0 S nil Miliary Tuberculosis 0.8 0.9 36 87 10.4 1.6 P N 218 174 N N 302 IV
11 27 M 0 0 S nil Acute bronchitis 0.9 0.6 22 62 7.8 1.13 N N 382 204 N N 26 III
12 44 M 0 0 S nil Viral hepatitis 1.2 3.9 48 392 9.4 1.6 P P 197.6 246 P N 21 IV
13 36 M 24 12 S nil Ischemic stroke 0.7 1.1 29 76 13.8 0.3 P P 396 207 N N 96 IV
14 42 F 24 6 S nil Chronic diarrhea 0.6 0.7 32 53 12 1.26 N N 179 212 N N 342 III
15 43 M 24 24 S nil Pancreatitis 1.2 3.4 60 178 6.2 1.38 P N 230 196 N N 532 IV
16 33 M 3 0 S nil Sepsis/MODS 6.7 22 75 368 12 1.4 P P 510.5 156 N N 309 IV
17 30 M 6 4 S nil Pancreatitis 0.8 0.9 18 80 9.1 1.2 P N 179 258 N N 887 IV
18 36 M 24 1 S nil Fever/Sepsis/Acute kidney injury 2.3 1.7 44 142 6.5 1.04 P N 198 214 N N 98 IV
19 40 M 0 0 S nil Pulmonary TB-sputum+/ 0.8 0.8 30 85 11.2 4.2 P P 240 442 N P 528 IV
20 65 M 0 0 S nil Ischemic stroke 1 0.9 38 91 9 1.52 N P 143 199 N N 89 IV
21 40 M 0 0 S nil Cryptococcal meningitis 1.3 0.8 57 79 8.3 0.9 P P 323 138 N N 47 IV
22 34 M 48 12 S nil RHD/LRI/ARDS 0.7 1 45 102 8 0.9 R P 146 959 N N 906 II
23 36 M 12 0 S nil Pulmonary TB 1 1.1 66 198 7.1 0.58 P P 128.7 902 N N 30 IV
24 39 M 36 0 S nil Pulmonary TB-relapse 1.1 0.7 28 78 12.6 1.71 P P 168 234 P N 386 IV
25 46 M 0 0 S nil Splenic abscess 1.4 0.9 35 186 4.2 1.27 P N 194 288 N N 31 IV
26 47 M 0 0 S nil Alcoholic hepatitis 1 16 120 122 10.6 1.03 P P 234 171 N N 116 IV
27 38 M 0 0 S nil Splenic candida 0.7 0.8 22 82 6.9 1.04 P N 82 392 N N 50 IV
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28 38 M 0 0 S nil Miliary TB 1.4 0.8 37 127 7.4 2.79 P P 91 427 N N 92 IV
29 53 F 4 0 S nil Acute bronchitis 0.9 0.8 26 61 9.3 1.45 P N 178 223 N N 355 III
30 42 M 48 12 S nil Alcoholic hepatitis 1.3 15 396 140 6.5 2.6 P P 94 520 N N 364 IV
31 66 M 60 60 S nil Chronic diarrhea 1 1.1 38 206 5.2 1.07 P P 142 241 N N 470 III
32 39 F 12 0 S nil Pulmonary TB-sputum +ve 1.1 0.8 34 114 4.1 1.29 N N 164 324 N N 245 III
33 39 M 24 0 S nil Cryptococcal meningitis 1 0.9 34 68 8 1.68 N N 118.1 214 N N 63 IV
34 49 F 0 0 S nil Splenic abscess 1.2 1 22 139 10.3 2.17 N N 194 228 N N 191 IV
35 55 M 24 24 S nil TB meningitis 0.9 0.9 36 101 8.8 0.75 N N 198 397 N N 180 IV
36 40 M 0 0 S nil Ischemic stroke 0.9 1 30 62 11 7.42 N N 117 314 N N 98 IV
37 25 M 5 0 S nil Chronic diarrhea 0.8 0.9 30 71 8.1 3.53 P P 150 256 N N 801 III
38 14 M 168 5 V nil Pancytopenia 0.9 0.8 20 85 2.2 0.89 N N 142.7 592 N N 353 III
39 29 M 48 48 S nil Peripheral neuropathy 1 0.8 39 76 8.8 1.4 N N 116 134 N N 106 IV
40 65 M 0 0 S nil Fever 1.4 1.8 46 88 9.5 1.15 P N 142 314 N N 81 II
41 34 M 24 4 S nil Pneumothorax/Pulmonary TB 0.9 0.7 37 65 8 1.4 N N 223 156 N N 112 III
42 35 M 6 6 S nil TB meningitis 0.7 0.9 28 120 7.4 2.17 P N 248 213 N N 106 IV
43 43 M 4 0 S nil DVT-upper limb 1 0.7 28 145 9.9 1.92 P N 198 163 N N 85 IV
44 28 M 24 0 S nil Sepsis/Cavernous sinus thrombosis 0.9 0.8 46 96 6.6 0.94 P N 57.2 313 N N 563 IV
45 37 F 12 12 S nil Drug reaction-SJS/Hepatitis 1 11 72 272 8.3 1.36 P P 180 286 N N 368 III
46 30 F 0 0 S nil Guillian Barre syndrome 0.6 0.8 36 41 9.9 2.85 N N 227 179 N N 123 IV
47 36 M 0 0 S nil Chronic diarrhea 1.5 1 30 84 10.7 2.66 P P 162 263 N N 365 III
48 25 F 4 3 S nil CMV retinitis/Pulmonary TB 1.6 0.9 45 105 7.7 1.61 N N 128 524 N N 68 IV
49 27 M 0 0 S nil Ischemic stroke 0.8 0.7 25 69 14.8 0.7 N R 484 164 N N 308 IV
50 42 M 0 0 S nil Chronic liver disease 1.9 0.9 37 101 7.3 1.91 P N 214 294 P N 114 IV
51 38 F 12 6 S nil nil 0.8 0.7 44 120 11 1.08 N N 195 186 N N 315 I
52 33 F 96 0 S nil nil 0.7 0.6 34 48 11.3 1.76 P N 183 192 N N 581 I
53 37 M 1 1 S nil Chronic diarrhea 0.9 0.7 30 45 10.6 1.92 N N 178 159 N N 68 III
54 32 F 0 0 S nil nil 0.8 0.9 36 98 10.7 1.98 N N 190 179 N N 475 I
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55 40 M 0 0 S nil RRTI/Fever 0.5 0.8 38 239 10.7 0.99 N N 186 231 N N 93 II
56 45 F 0 0 S nil Pneumonia 0.6 0.7 26 89 9 1.01 N N 203 234 N N 123 III
57 48 M 12 12 S nil nil 0.5 0.6 34 41 10 1.41 N N 179 312 N N 96 I
58 42 F 1 1 S nil nil 0.5 0.8 38 120 11 1.75 N N 242 190 N N 65 I
59 36 M 24 24 S nil nil 0.8 0.7 40 46 12.4 1.2 R N 233 231 N N 391 I
60 33 F 0 0 S nil Fever 0.6 0.7 32 46 11 2.1 R R 256 211 N N 466 I
61 30 M 24 24 S nil nil 0.6 1 58 51 9.1 1 N N 292 379 N N 158 I
62 31 F 72 0 S nil nil 0.7 0.8 24 48 10.9 1.14 N R 238 312 N N 579 I
63 24 F 64 64 S nil nil 0.5 0.7 26 56 10 1.66 P N 192 274 N N 285 I
64 31 M 60 60 S nil nil 0.8 0.6 34 56 11.7 1.28 N N 197 231 N N 642 I
65 29 F 60 12 S nil nil 0.7 0.8 28 52 11.3 1.34 N N 180 198 N N 709 I
66 34 F 24 24 S nil nil 0.7 0.7 36 54 12.3 2.4 N R 224 196 N N 549 I
67 43 F 3 3 S nil nil 0.6 0.8 44 68 11 1.88 P N 207 193 N N 109 I
68 36 F 36 24 S nil nil 0.9 0.9 28 84 10.5 1.8 N N 221 268 N N 381 I
69 40 M 2 2 S nil nil 0.8 0.7 30 64 10.8 1.3 P N 170 223 N N 93 I
70 30 F 0 0 S nil nil 0.8 0.9 31 54 11.3 2.12 N N 312 190 N N 479 I
71 46 M 72 72 S nil nil 0.6 0.7 34 46 11.4 1.03 N N 163 234 N N 534 I
72 35 F 12 12 S nil nil 0.7 0.8 31 56 10.4 2.13 N N 178 278 N N 125 I
73 45 M 0 0 S nil nil 0.6 0.9 33 36 11 2.39 P P 190 189 N N 423 I
74 28 F 0 0 S nil nil 0.8 0.6 34 39 10.8 1.24 N N 236 256 N N 378 I
75 40 M 24 24 S nil nil 0.7 0.8 36 58 11.8 1.34 N N 196 213 N N 403 I
76 43 M 2 2 S nil nil 1 0.6 46 78 12.3 1.99 N N 185 213 N N 67 I
77 40 M 8 0 S nil nil 0.8 0.9 46 52 11.5 2.6 N N 206 186 N N 371 I
78 34 F 34 1 S nil nil 0.5 1 48 63 11.6 2.4 P N 188 172 N N 249 I
79 35 F 24 0 S nil nil 0.8 0.8 31 52 10.8 1.22 R N 204 230 N N 441 I
80 30 F 24 0 S nil nil 0.6 0.8 33 46 11.9 1.1 N N 190 224 N N 456 I
81 47 M 82 7 S nil nil 0.8 0.7 32 56 11 1.86 N N 176 178 N N 141 I
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82 36 F 0 0 S nil Fever 0.8 0.9 24 144 7.1 1.9 P P 219 190 N N 180 III
83 33 F 0 0 S nil nil 0.7 0.8 32 76 10 1.32 P N 194 212 N N 545 I
84 46 F 2 2 S nil nil 1 0.8 34 52 11.1 1.23 N N 173 187 N N 340 I
85 32 F 82 82 S nil nil 0.8 0.6 42 50 13.2 2.34 P N 222 267 N N 791 I
86 50 M 0 0 S nil Chronic diarrhea 1.2 0.7 36 70 10.7 1.84 P N 194 220 N N 162 III
87 33 M 0 0 S nil Cellulitis 2.4 1.3 29 85 11.1 1.1 P N 156 197 N N 316 III
88 49 M 4 1 S nil Fever 0.8 0.7 21 80 8.2 1.57 P P 180 268 N N 268 III
89 47 F 48 48 S nil Carcinoma-cervix 1.3 0.9 25 86 9.5 1.06 P N 91 451 N N 370 IV
90 38 F 6 6 S nil nil 0.6 1 34 46 10.4 1.37 N N 186 268 N N 249 I
91 25 F 0 0 S nil Genital herpes 0.8 1.1 43 68 12.5 1 N R 199 265 N N 360 IV
92 33 M 0 0 S nil nil 0.7 1 36 42 13 1.72 N R 265 203 N N 423 I
93 44 F 72 0 S nil Recurrent oral ulcer 0.6 0.8 38 56 11.4 1.24 P N 211 185 N N 724 II
94 36 M 58 54 S nil nil 0.8 1.2 46 53 10.6 1.99 N N 256 223 N N 1247 I
95 47 M 2 2 S nil nil 0.9 1 28 45 12.4 1.87 P N 178 167 N N 160 I
96 34 M 36 36 S nil nil 0.7 1 45 92 10.6 1.45 N N 191 171 N N 203 I
97 37 M 27 24 S nil nil 0.6 0.8 43 65 11.8 1.89 N N 260 194 N N 158 I
98 30 F 28 3 S nil nil 0.8 1 24 38 11 1.6 N N 231 174 N N 266 I
99 34 F 82 82 S nil nil 0.8 0.9 42 63 10.9 1.72 P N 188 198 N N 709 I
100 56 M 82 46 S nil nil 0.7 0.8 28 41 11.6 2.1 P N 194 170 N N 435 I
ART-Anti-retroviral therapy,TB-Tuberculosis,PGL-Persistent generalised lymphadenopathy,CAD-Coronary artery disease,TBM-Tuberculous meningitis, 
ADD-Acute diarrheal disease,TB LN-Tuberculous lymphadenitis,MODS-Multiorgan dysfunction syndrome,RHD-Rheumatic heart disease,
DVT-Deep venous thrombosis,CMV-Cytomegalovirus,SJS-Stevens-Johnson syndrome,HBV-Hepatitis B virus,PR-Per rectum,DCM-Dilated cardiomyopathy
RRTI-Recurrent respiratory tract infection,PT,APTT(N-normal,P-prolonged,R-reduced)
HbsAg, AntiHCV-(P- Positive, N- Negative)
S-Sexual, V- Vertical
No.of in patients  (1 to 50)-50
No. of outpatients(51-100)-50
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1 35 F 0 0 sexual nil Ischemic stroke 0.7 0.8 46 75 8 2 N N 168 198 negative negative 108 IV Normal Negative
2 39 M 0 0 sexual nil Ischemic stroke/Viral hepatitis 1 6.8 118 92 11 0.8 P P 78 294 negative POSITIVE 88 IV Elevated Negative
3 36 M 24 12 sexual nil Ischemic stroke 0.7 1.1 29 76 14 0.3 P P 396 207 negative negative 96 IV Normal Positive
4 65 M 0 0 sexual nil Ischemic stroke 1 0.9 38 91 9 1.5 N P 143 199 negative negative 89 IV
5 40 M 0 0 sexual nil Ischemic stroke 0.9 1 30 62 11 7.4 N N 117 314 negative negative 98 IV Normal Negative
6 43 M 4 0 sexual nil DVT‐upper limb 1 0.7 28 145 9.9 1.9 P N 198 163 negative negative 85 IV Elevated Negative
7 28 M 24 0 sexual nil Sepsis/Cavernous sinus thrombosis 0.9 0.8 46 96 6.6 0.9 P N 57.2 313 negative negative 563 IV Elevated Negative
8 27 M 0 0 sexual nil Ischemic stroke 0.8 0.7 25 69 15 0.7 N N 484 164 negative negative 308 IV Normal Negative
PATIENT CONSENT FORM 
Study detail: 
“HEMOSTATIC STATUS IN HIV INFECTED INDIVIDUALS” 
Study centre  :             Rajiv Gandhi Government general hospital, Chennai. 
 
Patients Name  : 
Patients Age  : 
Identification Number        : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above study. I have the opportunity to 
ask question and all my questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical 
committee and the regulatory authorities will not need my permission to look at my health records, both 
in respect of current study and any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required under the law. I agree 
not to restrict the use of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual symptoms. 
I hereby consent to participate in  this study. 
I hereby  give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests. 
Signature/thumb impression:    
Patients Name and Address:                   Place   Date 
 
Signature of investigator :    
Study investigator’s Name :                               Place   Date      
 
 
